Krystal Biotech (KRYS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Krystal Biotech (KRYS)
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Key Insights
Critical company metrics and information
Share Price
$185.82Market Cap
$5.34 BillionTotal Outstanding Shares
28.76 Million SharesTotal Employees
229Dividend
No dividendIPO Date
September 20, 2017SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.krystalbio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Exchange Gains/Losses | $-4,000.00 |
Net Cash Flow, Continuing | $729,000.00 |
Net Cash Flow From Operating Activities | $63.34 Million |
Net Cash Flow From Financing Activities | $27.20 Million |
Net Cash Flow From Investing Activities | $-89.82 Million |
Net Cash Flow | $725,000.00 |
Net Cash Flow From Investing Activities, Continuing | $-89.82 Million |
Net Cash Flow From Operating Activities, Continuing | $63.34 Million |
Net Cash Flow From Financing Activities, Continuing | $27.20 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Average Shares | $28.88 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $184.12 Million |
Revenues | $241.52 Million |
Other Operating Expenses | $153.88 Million |
Research and Development | $51.42 Million |
Operating Expenses | $214.06 Million |
Net Income/Loss | $52.37 Million |
Diluted Earnings Per Share | $1.78 |
Basic Earnings Per Share | $1.85 |
Net Income/Loss Attributable To Parent | $52.37 Million |
Income/Loss From Continuing Operations Before Tax | $57.40 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income Tax Expense/Benefit | $5.03 Million |
Operating Income/Loss | $27.45 Million |
Benefits Costs and Expenses | $184.12 Million |
Diluted Average Shares | $30.04 Million |
Net Income/Loss Available To Common Stockholders, Basic | $52.37 Million |
Income/Loss From Continuing Operations After Tax | $52.37 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Assets | $106.28 Million |
Liabilities And Equity | $982.32 Million |
Fixed Assets | $156.59 Million |
Current Liabilities | $89.53 Million |
Equity | $885.85 Million |
Noncurrent Assets | $269.15 Million |
Other Current Liabilities | $83.95 Million |
Inventory | $18.58 Million |
Assets | $982.32 Million |
Noncurrent Liabilities | $6.95 Million |
Current Assets | $713.16 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $5.58 Million |
Other Non-current Assets | $112.56 Million |
Cash | $588.30 Million |
Equity Attributable To Parent | $885.85 Million |
Liabilities | $96.47 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.